Entrada Therapeutics has secured authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and ...

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at ...

Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

Natural "off switch" could slow or even reverse the growth of aggressive tumors.

The integration of naturalized players into the Chinese national team marked a significant milestone in the nation’s football history. Initially, players like Exon, Alan, and Fernando were seen as key ...

The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions ...

A committee advanced a bill to provide Nebraska constitutional officers, except the governor, a roughly 57% salary raise in ...

New companion diagnostics (CDx) collaboration announced with Bayer in China in May 2024.

Entrada Therapeutics Inc. has received authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and research ethics committee to initiate a phase I/II study of ENTR-601 ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

Intech Investment Management LLC boosted its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 99.3% in the 4th quarter, according to its most recent disclosure with the ...